Introduction {#Sec1}
============

Graves ophthalmopathy is a complex of ocular symptoms accompanying autoimmune thyroid diseases. In 90% of cases, it is associated with hyperthyreosis. In the other 10% of cases, it is diagnosed in euthyreotic patients, and is called ocular Graves disease, or in hypothyreotic patients (and then it is most frequently associated with Hashimoto disease) \[[@CR40]\]. Modern imaging techniques revealed that ocular symptoms occur in almost all patients with hyperthyreosis \[[@CR11], [@CR12], [@CR69], [@CR73], [@CR74]\]. These are usually benign lesions (non-infiltrative ophthalmopathy) that subside totally after normal thyroid function is restored \[[@CR11], [@CR18], [@CR49], [@CR70], [@CR73]\]. About 5--10% of patients with hyperthyreosis develop Graves ophthalmopathy of a progressive course that may lead to severe ocular complications \[[@CR28], [@CR73], [@CR74]\]. Sometimes only involvement of oculomotor muscles is found without exophthalmos. Optic neuropathy, corneal ulcerations and perforations with consequent blindness may occur \[[@CR21], [@CR28], [@CR73], [@CR74]\].

In the treatment of infiltrative ophthalmopathy, irrespective of thyroid function control, there is a necessity to reduce the volume of oedematous swollen intraorbital tissues to expand free space inside the orbit. To achieve the above glycocorticosteroid treatment, radiotherapy, combination of both methods or surgical orbital decompression are used \[[@CR1], [@CR7], [@CR11], [@CR35], [@CR36], [@CR42], [@CR65], [@CR71], [@CR72], [@CR73]\]. Surgical decompression reduces only mechanical effects of exophthalmos and usually, sooner or later, requires subsequent glycocorticosteroid therapy. Effectiveness of glycocorticosteroids (recently administered in the form of pulses of methylprednisolone acetate) is found to be 60% \[[@CR11], [@CR37], [@CR58], [@CR64], [@CR73]\].

Starting from the year 1983, high doses of glycocorticosteroid are combined with orbital radiotherapy \[[@CR5]\]. Glycocorticosteroid therapy provides quick improvement of ocular symptoms and prevents transient worsening of these symptoms as the result of radiotherapy \[[@CR11], [@CR16], [@CR29], [@CR42], [@CR53], [@CR67]\]. Irradiation consolidates the effects of steroid therapy and decreases the risk of ocular symptoms relapse \[[@CR9], [@CR11], [@CR16], [@CR57], [@CR73]\]. Radiotherapy has unspecific anti-inflammatory and specific immunosupressive effects on both mediators (lymphocytes) and effectors (fibroblasts) of the immune reaction in the orbit \[[@CR56], [@CR74]\]. The optimal irradiation dose in the treatment of Graves ophthalmopathy is 20 Gy in ten fractions administered within 2 weeks \[[@CR11], [@CR27], [@CR30], [@CR31], [@CR39], [@CR56], [@CR62], [@CR73]--[@CR75]\].

This paper summarizes my own experience in the treatment of Graves ophthalmopathy.

Materials and methods {#Sec2}
=====================

From January 2000 to December 2003, the team of the Clinic of Oncology of the Jagiellonian University Medical College performed radiotherapy of the retrobulbar area in 121 patients (91 female---75.2% and 30 males---24.8%). Mean age was 55.1 years (range, 32--85). One hundred sixteen out of 121 (95.9%) patients received previously in the Clinic of Endocrinology intravenous treatment with methylprednisolone acetate at the dose of 2 g/week for four consecutive weeks.

Five patients (4.1%) did not receive glycocorticosteroids due to: contraindications (two patients), improvement of ocular symptoms after treatment with methimazole (except persistent symptoms within the peribulbar soft tissue; two patients) and due to refusal of consent for steroid treatment (one patient).

Twelve months after the treatment was completed, in 106/121 patients ophthalmologic examination and orbital CT scan were performed. Three out of the remaining 15 patients died before the follow-up visit and 12 refused to undergo the follow-up procedures. Clinical characteristics of 101 patients subject to further analysis are presented in Table [1](#Tab1){ref-type="table"}. Table 1Characteristics of 101 patients treated with the combined methodMean age52.3 years (32-81)Sex Males26 (25.7%) Females75 (74.3%)Time from the onset of ocular symptoms to the start of the combined treatment16.8 months (4-116 months)Smoking No50 (49.5%) Yes49 (48.5%) Unknown2 (2%)Diabetes No89 (88.1%) Yes12 (11.9%)Thyroid status at the moment of exophthalmos diagnosis Normal16 (15.8%) Hyperthyreosis74 (73.3%) Unknown11 (10.9%)Treatment of hyperthyreosis No17 (16.8%) Yes84 (83.2%)Pre-treatment fT4 level (normal range, 11--22 pmol/l) Normal74 (73.3%) Elevated5 (5%) Lowered16 (15.8%) No data6 (5.9%)Pre-treatment TSH level: (normal range, 0.2--6.5 μU/mol) Normal70 (69.3%) Elevated7 (6.9%) Lowered24 (23.8%)

As shown in the table above, mean age in the combined treatment group was 52 years. Female patients, non-smokers and non-diabetics predominated. Mean time from the onset of ocular symptoms to the treatment start was 16 months. The majority of patients was previously treated for hyperthyreosis (61/101 i.e. 60.4%) and was hyperthyreotic at the time of exophthalmos onset. However, at the moment of referral for radiotherapy, the majority of patients had normal fT4 and thyroid-stimulating hormone (TSH) levels.

The subsequent analysis will involve two groups of patients: One hundred one101 patients previously treated with intravenous steroids (assessed before radiotherapy),Ninety-three patients out of 101 patients in group A treated with the combined method, i.e., with steroid therapy with subsequent radiotherapy to the total dose of 20 Gy in ten fractions (assessed after radiotherapy).

Irradiation technique {#Sec3}
---------------------

Before the start of radiotherapy assessed individual celone moulds were done for all patients. In all patients, orbital CT scans were done for treatment planning. CT slice thickness was 3 mm. Two opposite isocentric beam techniques were used to cover the retrobulbar area. Beam angles were adjusted for divergence to form coincident plane behind lenses (Fig. [1](#Fig1){ref-type="fig"}). Extraorbital structures were individually shielded with Wood alloy shields. Irradiation was performed with a 6 MeV photon beam emitted by the Mevatron Primus accelerator. The planned irradiation dose was 20 Gy in ten fractions. Treatment planning was done in a 3D treatment planning system---TMS Helax. Fig. 1The arrangement of beams and the dose distribution during irradiation of the retrobulbar area in Graves-Basedow disease

Assessment of treatment efficacy {#Sec4}
--------------------------------

The following methods were used to assess the efficacy of the treatment: medical history, ophthalmologic examination and CT scan of the retrobulbar areas. Ophthalmologic examination was done before the start of the treatment and 12 months after treatment completion. During the examination the NOSPECT score system was used to define severity of ophthalmopathy based on such parameters as: soft tissues (i.e., conjunctiva, eyelids), exophthalmos, oculomotor muscle dysfunction, condition of the cornea and vision. These symptoms were attributed scores: 1--2--3, depending on symptom severity. Eyelids and conjunctiva: 1---minor reddening of conjunctiva or moderate eyelid oedema, 2---significant reddening of conjunctiva or major eyelid oedema, 3---severe inflammatory condition of the above structures. Exophthalmos was measured with exophthalmometer: 20--24 mm scored---1, 24--27 mm---2, above 27 mm---3. Oculomotor muscle involvement: eye globe mobility impairment in extreme eye positions---1, significant impairment of eye globe mobility---2, immobilisation of one or both eye globes---3. Cornea: single epithelial defects (with fluorescein staining)---1, moderate epithelial defects---2, extensive epithelial defects---3. Snellen chart was used for vision assessment. Vision defect ranging from 0.67--0.33 scored 1, 0.32--0.10---2, below 0.10---3. CT scan of retrobulbar areas was performed in all patients before the start the treatment and after 12 months of treatment completion. Based on CT of retrobulbar area the following parameters were assessed: thickness of the recti muscles and lacrimal glands, volume of the retrobulbar fat and optic nerve condition.

Statistical analysis {#Sec5}
--------------------

Qualitative parameters were characterised by percentage distribution. Relationships between qualitative parameters, including assessment of the treatment effect, were evaluated with chi square independent test. To compare particular treatment stages the case--control method and Fisher test was used. *p* value was calculated for all tests.

Results {#Sec6}
=======

Evaluation of the treatment with steroids {#Sec7}
-----------------------------------------

Treatment results as assessed by ophthalmologic examination in the group of patients treated previously with intravenous steroids (situation before radiotherapy) are presented in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Table 2Treatment results as assessed by ophthalmologic examination in the group of patients treated previously with intravenous steroids (*n* = 101)---the right eyeNOSPECTThe right eye before steroid treatmentThe right eye after steroid treatmentp (Mc Nemara test)Soft tissuesNormal15/101 (14.8%)15/42 (35.7%)0.0059Grade 31/101 (1.0%)0/42 (0.0%)0.5165Grade 233/101 (32.7%)0/42 (0.0%)Grade 152/101 (51.5%)27/42 (64.3%)Not examined0/101 (0.0%)59/101 (58.4%)ExophthalmosNormal46/101 (45.5%)18/42 (42.8%)0.7678Grade 32/101 (2.0%)1/42 (2.4%)0.8799Grade 212/101 (11.9%)5/42 (11.9%)Grade 141/101 (40.6%)18/42 (42.8%)Not examined0/101 (0.0%)59/101 (58.4%)Oculomotor musclesNormal23/101 (22.8%)12/42 (28.6%)0.4639Grade 36/101 (5.9%)0/42 (0.0%)0.1101Grade 235/101 (34.7%)11/42 (26.2%)Grade 137/101 (36.6%)19/42 (45.2%)Not examined0/101 (0.0%)59/101 (58.4%)CorneaNormal88/101 (87.2%)36/42 (85.7%)0.8099Grade 30/101 (0.0%)0/42 (0.0%)1.0000Grade 20/101 (0.0%)0/42 (0.0%)Grade 113/101 (12.8%)6/42 (14.3%)Not examined0/101 (0.0%)59/101 (58.4%)Visual acuityNormal8/101 (7.9%)1/42 (2.4%)0.2191Grade 30/101 (0.0%)0/42 (0.0%)1.0000Grade 20/101 (0.0%)0/42 (0.0%)Grade 193/101 (92.1%)41/42 (97.6%)Not examined0/101 (0.0%)59/101 (58.4%)Table 3Treatment results as assessed by ophthalmologic examination in the group of patients treated previously with intravenous steroids (*n* = 101)---the left eyeNOSPECTThe left eye before steroid treatmentThe left eye after steroid treatmentp (Mc Nemara)Soft tissuesNormal14/101 (13.8%)16/42 (38.1%)0.0014Grade 31/101 (1.0%)0/42 (0.0%)0.5165Grade 232/101 (31.7%)0/42 (0.0%)Grade 154/101 (53.5%)26/42 (61.9%)Not examined0/101 (0.0%)59/101 (58.4%)ExophthalmosNormal54/101 (53.5%)23/42 (54.8%)0.8873Grade 34/101 (3.9%)0/42 (0.0%)0.1965Grade 212/101 (11.9%)6/42 (14.3%)Grade 131/101 (30.7%)13/42 (30.9%)Not examined0/101 (0.0%)59/101 (58.4%)Oculomotor musclesNormal15/101 (14.9%)9/42 (21.4%)Grade 35/101 (4.9%)0/42 (0.0%)0.3454Grade 237/101 (36.6%)12/42 (28.6%)0.1465Grade 144/101 (43.6%)21/42 (50.0%)Not examined0/101 (0.0%)59/101 (58.4%)CorneaNormal88/101 (87.1%)33/42 (78.6%)0.2017Grade 31/101 (1.0%)0/42 (0.0%)0.5165Grade 21/101 (1.0%)0/42 (0.0%)Grade 111/101 (10.9%)9/42 (21.4%)Not examined0/101 (0.0%)59/101 (58.4%)Visual acuityNormal6/101 (5.9%)0/42 (0.0%)0.1101Grade 32/101 (2.0%)0/42 (0.0%)0.3576Grade 20/101 (0.0%)0/42 (0.0%)Grade 193/101 (92.1%)42/42 (100.0%)Not examined0/101 (0.0%)59/101 (58.4%)

Based on the above table, significant improvement within right peribulbar soft tissues following intravenous steroid therapy may be shown (*p* \< 0.05). Nevertheless, this observation is weakened by the fact that in half of the patients, post-treatment ophthalmologic assessment is missing.

Based on the above table, significant improvement within left peribulbar soft tissues following intravenous steroid therapy may be shown (*p* \< 0.05). Nevertheless, this observation is weakened by the fact that in half of the patients, post-treatment ophthalmologic assessment is missing.

Treatment results as assessed by computed tomography (CT) of the retrobulbar areas 12 months after treatment completion in the group of patients treated previously with intravenous steroid therapy.

Treatment results are presented in Table [4](#Tab4){ref-type="table"}. Table 4Treatment results as assessed by computed tomography (CT) of the retrobulbar areas in the group of patients treated previously with intravenous steroid therapy (*n* = 101)Left eye after treatment completion---improvementRight eye after treatment completion---improvementThickness of the superior rectus muscle0/43 (0.0%)0/43 (0.0%)Thickness of the inferior rectus muscle0/54 (0.0%)0/48 (0.0%)Thickness of the lateral rectus muscle0/33 (0.0%)0/28 (0.0%)Thickness of the median rectus muscle0/71 (0.0%)0/68 (0.0%)Fat tissue1/21 (4.8%)0/18 (0.0%)Optic nerve0/1 (0.0%)0/0 (0.0%)Lacrimal gland0/1 (0.0%)0/2 (0.0%)*numerator* the number of patients with improvement, *denominator* the number of patients with particular symptoms at baseline

As shown in the table above, no improvement was found within the right eye as assessed with computed tomography. Only slight improvement of the left eye condition was observed, in terms of reduction of the retrobulbar fat tissue.

Evaluation of efficacy of the combined treatment {#Sec8}
------------------------------------------------

Treatment results as assessed by ophthalmologic examination.

The results are presented in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}. Table 5Treatment results as assessed by ophthalmologic examination in the group of patients treated with steroids and full-dose radiotherapy 20 Gy/10 fractions (*n* = 93)---the right eyeNOSPECTRight eye before treatmentRight eye 12 months after treatmentp (Mc Nemara)ExophthalmosNormal42/93 (45.2%)42/87 (48.3%)0.2561Grade 32/93 (2.1%)0/87 (0.0%)Grade 211/93 (11.8%)12/87 (13.8%)Grade 138/93 (40.9%)33/87 (37.9%)Not examined0/93 (0.0%)6/93 (6.45%)Soft tissuesNormal14/93 (15.1%)48/83 (57.8%)0.1945Grade 31/93 (1.1%)0/83 (0.0%)Grade 230/93 (32.3%)2/83 (2.4%)Grade 147/93 (50.5%)33/83 (39.8%)Not examined0/93 (0.0%)10/93 (10.8%)Oculomotor musclesNormal21/93 (22.6%)43/83 (46.2%)0.8200Grade 36/93 (6.4%)0/83 (0.0%)Grade 233/93 (35.5%)4/83 (4.3%)Grade 134/93 (36.6%)36/83 (38.7%)Not examined0/93 (0.0%)10/93 (10.8%)CorneaNormal80/93 (86.0%)79/83 (95.2%)0.8816Grade 30/93 (0.0%)0/83 (0.0%)Grade 20/93 (0.0%)0/83 (0.0%)Grade 113/93 (14.0%)4/83 (4.8%)Not examined0/93 (0.0%)10/93 (10.8%)Visual acuityNormal7/93 (7.5%)4/83 (4.8%)0.1046Grade 30/93 (0.0%)0/83 (0.0%)Grade 20/93 (0.0%)0/83 (0.0%)Grade 186/93 (92.5%)79/83 (95.2%)Not examined0/93 (0.0%)10/93 (10.8%)Table 6Treatment results as assessed by ophthalmologic examination in the group of patients treated with steroids and full-dose radiotherapy 20 Gy/10 fractions (*n* = 93)---the left eyeNOSPECTLeft eye before treatmentLeft eye 12 months after treatmentp (Mc Nemara)ExophthalmosNormal49/93 (52.7%)48/86 (55.8%)0.0698Grade 33/93 (3.2%)0/86 (0.0%)Grade 212/93 (12.9%)6/86 (7.0%)Grade 129/93 (31.2%)32/86 (37.2%)Not examined0/93 (0.0%)7/93 (7.5%)Soft tissuesNormal14/93 (15.0%)41/74 (55.4%)0.2942Grade 31/93 (1.1%)0/74 (0.0%)Grade 229/93 (31.2%)1/74 (1.4%)Grade 149/93 (52.7%)32/74 (43.2%)Not examined0/93 (0.0%)19/93 (20.4%)Oculomotor musclesNormal15/93 (16.1%)35/83 (42.2%)0.3332Grade 35/93 (5.4%)0/83 (0.0%)Grade 232/93 (34.4%)5/83 (6.0%)Grade 141/93 (44.1%)43/83 (51.8%)Not examined0/93 (0.0%)10/93 (10.8%)CorneaNormal80/93 (86.0%)76/82 (92.7%)0.8216Grade 31/93 (1.1%)0/82 (0.0%)Grade 21/93 (1.1%)0/82 (0.0%)Grade 111/93 (11.8%)6/82 (7.3%)Not examined0/93 (0.0%)11/93 (11.8%)Visual acuityNormal6/93 (6.4%)5/83 (6.0%)0.1696Grade 31/93 (1.1%)1/83 (1.2%)0.9700Grade 20/93 (0.0%)0/83 (0.0%)Grade 186/93 (92.5%)77/83 (92.8%)Not examined0/93 (0.0%)10/93 (10.7%)

Based on the table, no effect of intravenous steroid therapy followed by radiotherapy was found within the right eye, as assessed by ophthalmologic examination (no statistical significance).

Based on the table, no effect of intravenous steroid therapy followed by radiotherapy was found within the left eye, as assessed by ophthalmologic examination (no statistical significance).

Treatment results as assessed by computed tomography (CT) of the retrobulbar areas.

Treatment efficacy measured with CT of retrobulbar areas is presented in Table [7](#Tab7){ref-type="table"}. Table 7Treatment results as assessed by computed tomography (CT) of the retrobulbar areas in the group of patients treated with steroids and full-dose radiotherapy 20 Gy/10 fractions (*n* = 93)Left eye after treatment completion---improvementRight eye after treatment completion---improvementThickness of the superior rectus muscle0/41 (0.0%)0/41(0.0%)thickness of the inferior rectus muscle0/51 (0.0%)0/45 (0.0%)Thickness of the lateral rectus muscle0/30 (0.0%)0/26 (0.0%)Thickness of the median rectus muscle0/68 (0.0%)0/63 (0.0%)Fat tissue2/21 (9.5%)0/18 (0.0%)Optic nerve1/1 (100%)0/0 (0.0%)Lacrimal gland0/1 (0.0%)0/2 (0.0%)*numerator* the number of patients with improvement, *denominator* the number of patients with particular symptoms before the treatment

As shown in the table, no improvement was achieved within the right eye after the combined treatment, as assessed by computed tomography. Some improvement was achieved within the left eye in terms of fat tissue reduction and decrease of optic nerve oedema. However, this observation is based on a relatively small group of patients.

Comparison of treatment results {#Sec9}
-------------------------------

Improvement after the treatment of malignant exophthalmos was mostly of subjective nature. Therefore, evaluation of efficacy of particular treatment methods was limited to the patient self-reported results (Table [8](#Tab8){ref-type="table"}). Table 8Patient self-reported eye symptoms improvement by treatment methodSymptomSteroid therapy n = 101Combined therapy n = 93p (Fisher test)ABUnilateral or bilateral exophthalmos49/97 (50.5%)71/89 (79.8%)A/B 0.0000Oedema of the peribulbar soft tissue39/96 (40.6%)56/88 (63.7%)A/B 0.0020Diplopia50/93 (53.8%)47/85 (55.3%)A/B 0.8809Eye burning/lacrimation35/91 (38.5%)61/84 (72.6%)A/B 0.0000Pain and/or eye pushing-out sensation27/81 (33.3%)56/76 (73.7%)A/B 0.0000Visual acuity26/50 (52.0%)26/47 (55.3%)A/B 0.8392Colour vision4/7 (57.1%)5/6 (83.3%)A/B 0.5594*numerator* the number of patients with improvement, *denominator* the number of patients reporting particular symptoms at baseline

As demonstrated in the table above, the highest efficacy with respect to improvement of all ocular symptoms was found after the combined treatment. Taking into consideration the fact that the combined treatment of ophthalmopathy was the most effective one, the effect of prognostic factors on the results of this treatment was studied. It was shown that females and non-diabetic patients respond favourably to the combined treatment (Tables [9](#Tab9){ref-type="table"} and [10](#Tab10){ref-type="table"}). Such factors as patient age, ocular symptoms duration, smoking and thyroid function did not affect treatment results (no statistical significance was demonstrated). Table 9Improvement of ocular symptoms by sex in the group of patients treated with the combined method (*n* = 93)SymptomMen improvementWomen improvementChi squareExophthalmos16/22 (72.7%)54/67 (80.6%)0.4345Oedema15/22 (68.2%)40/66 (60.6%)0.5250Diplopia8/22 (36.4%)38/63 (60.3%)0.0523Eye burning/tearing10/20 (50.0%)50/64 (78.1%)0.0151^a^Pain/eye pushing-out sensation13/17 (76.5%)41/58 (70.7%)0.6406Visual acuity4/12 (33.3%)22/35 (62.8%)0.0759Colour vision0/0 (0.0%)5/5 (100%)*numerator* the number of patients with improvement, *denominator* the number of patients (by sex) with particular symptoms at baseline^a^Statistically significant difference (*p* \< 0.05)Table 10Improvement of ocular symptoms in diabetic and non-diabetic patients in the group treated with the combined method (*n* = 93)SymptomDiabetics improvementNon-diabetics improvementChi squareExophthalmos6/11 (54.6%)65/78 (83.3%)0.0261^a^Oedema6/12 (50.0%)50/76 (65.8%)0.2907Diplopia2/11 (18.2%)44/73 (60.3%)0.0089^a^Eye burning/tearing5/12 (41.7%)56/72 (77.8%)0.0094^a^Pain/eye pushing-out sensation5/9 (55.6%)51/67 (76.1%)0.1884Visual acuity3/6 (50.0%)23/41 (56.1%)0.7790Colour vision1/2 (50.0%)4/4 (100%)0.1213*numerator* the number of patients with improvement, *denominator* the number of non-diabetics/diabetics with particular symptoms^a^Statistically significant difference (*p* \< 0.05)

Toxicity of radiotherapy {#Sec10}
------------------------

Acute reaction occurred in 11/121 patients (9.1%) during radiotherapy. Symptoms of acute reactions are presented in Table [11](#Tab11){ref-type="table"}. Table 11Symptoms of acute reaction in the group of 121 patients with Graves ophthalmopathy occurring during radiotherapy of retrobulbar areasAcute post-irradiation reactionn = 121Significant tearing and eyelid oedema3 (2.5%)Erythema in high-dose areas3 (2.5%)Slight tearing2 (1.6%)Erythema and eye burning sensation1 (0.8%)Aggravation of diplopia and worsening of visual acuity1 (0.8%)Aggravation of tearing and worsening of visual acuity1 (0.8%)

Acute reaction symptoms were mild to moderate and transient. Acute reaction in the diabetic group was not worse than average.

During follow-up after treatment completion in the group of 106 patients, three cases of cataract were diagnosed that were rather related to physiological ageing process than to radiotherapy. No diabetic retinopathy was found in the diabetic group.

Symptoms of late post-irradiation reaction are presented in Table [12](#Tab12){ref-type="table"}. Table 12Symptoms of late post-irradiation reaction found during follow-up after treatment completion in the group of 101 patients with Graves ophthalmopathyLate post-irradiation reactionn = 101Retinopathy0 (0.0%)Cataract3 (2.8%)Radiation-induced tumours0 (0.0%)

Discussion {#Sec11}
==========

Aetiology of ophthalmopathy is not fully understood; therefore, its treatment is usually of palliative nature and the purpose of this treatment is to inhibit progression of the disease and of functional eye disorders as well as improvement of patient's appearance \[[@CR11], [@CR36], [@CR73]\]. Diagnostic criteria, selection of the treatment method as well as Graves ophthalmopathy treatment results are still the matter of controversy \[[@CR12], [@CR18], [@CR22], [@CR25], [@CR38], [@CR48], [@CR51], [@CR57], [@CR63], [@CR64]\]. Diagnosis is based mainly on clinical data \[[@CR4], [@CR12], [@CR33], [@CR54], [@CR62], [@CR64]\]. In the analysed material, the most common complaints (most 95% of patients) were related to exophthalmos and in 75% of patients (89/121) ocular symptoms were accompanied by hyperthyreosis. In the remaining 25% of patients, orbital CT scan was necessary to explain the cause of ocular symptoms. The most important for diagnosis of Graves ophthalmopathy is evaluation of the oculomotor muscles diameters with maximum normal values of 4.9 mm (−/+0.5 mm) \[[@CR64]\].

The decision concerning the treatment of malignant exophthalmos must be based on assessment of two elements: severity of the symptoms and the level of disease control \[[@CR3], [@CR11]\]. An obvious reflection of disease severity is a significantly limited field of vision related to infiltration of the optic nerve, as well as significant exophthalmos \[[@CR11]\]. A separate problem is the level of disease activity. It seems that after a period of progression, malignant exophthalmos enters the phase of partial remission followed by a stationary period. Additionally, exophthalmos activity level does not correlate with symptoms severity \[[@CR11]\].

Glycocorticosteroids may be used in the oral (prednisone), retrobulbar/subconjunctival or intravenous (methylprednisolone acetate) forms \[[@CR11], [@CR29], [@CR44], [@CR64], [@CR73]\]. The intravenous route seems to be the most effective one, particularly with respect to the soft tissue symptoms and optic neuropathy \[[@CR9]--[@CR11]\]. The effect of steroid therapy on exophthalmos and eye globe mobility is only a minor one \[[@CR11]\]. Improvement is found in about 60% of patients with infiltrative ophthalmopathy \[[@CR11], [@CR64], [@CR73]\]. Additionally, this treatment is associated with numerous side effects \[[@CR11], [@CR26], [@CR29], [@CR42], [@CR44], [@CR51], [@CR53], [@CR73]\].

The efficacy of radiotherapy alone in the treatment of Graves ophthalmopathy is assessed to be about 60% \[[@CR6], [@CR20], [@CR27], [@CR30], [@CR57], [@CR58], [@CR62], [@CR64], [@CR73]\]. In the discussed material, only five patients were treated with radiotherapy alone. The above treatment was mostly effective in elimination of eye burning sensation and lacrimation, peribulbar tissue oedema and pain and/or eye pushing-out sensation. The follow-up ophthalmologic examination suggests improvement of vision acuity and CT scan, improvement of optic nerve condition. It could be accordant with literature data but the relatively low number of the observed patients makes it difficult to draw any conclusions \[[@CR2], [@CR19], [@CR50]\].

In the discussed material, acute reaction to radiotherapy occurred in 11/121 patients (9.1%) and it was transient in nature. Radiation sequent reported in the literature such as: palpebral erythema, periorbital and conjunctival oedema, headache, hair loss, blurred vision were also transient and mild in nature \[[@CR14], [@CR17], [@CR34], [@CR47], [@CR52], [@CR55], [@CR60], [@CR65], [@CR73], [@CR74]\].

Late complications following radiotherapy of retrobulbar area include: retinopathy, cataract and radiation-induced tumours \[[@CR9], [@CR13]--[@CR15], [@CR17], [@CR23], [@CR24], [@CR26], [@CR29], [@CR42], [@CR43], [@CR45], [@CR46], [@CR51], [@CR59], [@CR61], [@CR65], [@CR66], [@CR68], [@CR73]\]. In the presented material, three cases of cataract (three out of 106 = 2.8%) were reported that however might have been related to the physiological ageing process and not to radiotherapy. In the group of diabetic patients (12/93 = 12.9%) no diabetic retinopathy was found after the combined treatment. Until now, no secondary tumours were found within the previously irradiated area.

At least two controlled studies showed that combination of high-dose steroid therapy with radiotherapy is the most effective treatment of malignant exophthalmos \[[@CR5], [@CR11], [@CR41], [@CR75]\]. In the analysed material, the vast majority of patients were treated with the combined method (93/101). Based on the follow-up ophthalmologic examination, it was shown the intravenous steroid therapy followed by radiotherapy is effective with respect to normalisation of soft tissue and oculomotor muscles condition as well as exophthalmos improvement.

The following factors are considered to worsen the prognosis of ophthalmopathy: patient age above 50--60 years, male sex, smoking, symptom duration, concomitant diabetes, hyperthyreosis \[[@CR2], [@CR5], [@CR8], [@CR9], [@CR13], [@CR14], [@CR25], [@CR26], [@CR30], [@CR32], [@CR45], [@CR49], [@CR51], [@CR52], [@CR58], [@CR59], [@CR70]\]. The effect of these factors was analysed in the group of patients treated with the most effective method, i.e. with the combined method. Patient age, symptom duration, smoking, TSH and fT4 levels did not affect significantly the results of the malignant exophthalmos treatment---in contrast to concomitant diabetes and male sex.

Graves ophthalmopathy treatment available at present is not fully satisfactory. Its efficacy is assessed to be about 60--80% \[[@CR46], [@CR51]\]. Therefore, new treatment methods are tested. Use of cytokine antagonists, in particular, penthoxiphyline, somatostatin analogues and colchicine seems to be the most promising among them \[[@CR10], [@CR36], [@CR64], [@CR73]\].

However, the majority of centres consider combined steroid and radiotherapy treatment to be, at present, the best treatment method for Graves ophthalmopathy \[[@CR31], [@CR57], [@CR64], [@CR67], [@CR73], [@CR75]\].

Conclusions {#Sec12}
===========

Radiotherapy combined with steroid therapy in the treatment of Graves ophthalmopathy seems to be an effective treatment of malignant exophthalmos symptoms at strictly defined indications.Radiotherapy is a well-tolerated treatment modality in Graves ophthalmopathy.Diabetes mellitus is a factor worsening prognosis in Graves ophthalmopathy.Female sex is a favourable prognostic factor in Graves ophthalmopathy.

**Conflict of interest statement** There is no conflict of interest related to this paper.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
